AKT1 and cancer: Furthermore, NVP-BEZ235 targets the mammalian target of rapamycin (mTOR) results decreasing the expression levels of phosphorylated Akt, inducing cancer cell death invitro and inhibiting cancer cell proliferation in vivo [160].